☆ 4.7 Meeting Abstract

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)

ANNALS OF ONCOLOGY (2019)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 30, Issue -, Pages 710-+

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdz264

Keywords

-

Categories

Oncology

Funding

  1. F. Hoffmann-La Roche, Ltd.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.